Institutional Investors Boost Holdings in Rocket Lab Despite Neutron Delay

Rocket Lab's record $1.85B backlog attracts major institutional investment from Quadrature Capital and Vanguard, despite a delay in its Neutron rocket launch to late 2026.

Major asset managers are increasing their stakes in Rocket Lab USA, signaling sustained confidence even as the company navigates a significant setback in its flagship development program. The contrasting picture of a record backlog paired with a postponed rocket debut is drawing focused institutional interest.

Financial Performance and Strategic Contracts

Rocket Lab's fiscal year 2025 results, released in late February, provided the catalyst for recent investment activity. The company reported fourth-quarter revenue of $179.6 million. More notably, its backlog surged to an all-time high of $1.85 billion, representing a substantial 73% increase year-over-year. A pivotal $816 million contract with the U.S. Space Development Agency for missile warning and tracking satellites was a primary driver of this growth.

This robust demand is translating into direct investment. Based on mandatory filings dated March 13, Quadrature Capital significantly expanded its position, boosting its share count by 121% to a total of 391,213 shares—an acquisition valued at approximately $18.75 million. Separately, Vanguard Group also increased its holdings, now possessing nearly 41.8 million shares, a rise of about 5.4%.

Development Hurdle for Next-Generation Rocket

The investment inflows arrive alongside challenging news for Rocket Lab's future roadmap. The inaugural launch of its medium-lift Neutron rocket has now been scheduled for the fourth quarter of 2026. This delay follows an anomaly encountered during a stage tank test in January 2026, which necessitated further engineering work.

While Neutron awaits its debut, the company's operational workhorse, the Electron rocket, continues its reliable service. The successful completion of Mission 83 recently underscored this operational consistency. For the institutional buyers, the deferred Neutron timeline does not appear to be a deterrent; the massive order book is viewed as a clear indicator of long-term demand for launch capacity.

Shareholder Scrutiny and Market Position

Shareholders will have their first formal opportunity to assess the Neutron program's progress and management's capital allocation strategy at the annual meeting on May 20, 2026. The deadline for shareholder proposals and director nominations is March 22, 2026.

In the market, Rocket Lab's shares currently trade approximately 10% below their 50-day moving average. Although the stock has retreated since the start of the year, it remains positioned notably above its 200-day moving average, reflecting a tempered but persistent investor outlook.